Ultra high performance liquid chromatography coupled with high resolution quantitation mass spectrometry method development and validation for determining genotoxic 2,5-dichlorobenzoyl chloride in MLN9708 drug substance.

A novel reversed-phase ultra high performance liquid chromatography coupled with high resolution quantitation mass spectrometry (UHPLC/HRQMS) method was developed to quantify 2,5-dichlorobenzoyl chloride (DCBC), a genotoxic impurity, in MLN9708 drug substance. A surrogate strategy was utilized whereby DCBC was intentionally hydrolyzed to 2,5-dichlorobenzoic acid (DCBA) to provide a stable and reliable detection target. The hydrolysis approach was conservative since the measured signal represented the sum of DCBC and DCBA in MLN9708 drug substance, and such approach was acknowledged and accepted by food and drug administration (FDA). HRQMS was used as the detection method since conventional MS/MS methodology gave poor sensitivity and selectivity due to non-specific fragmentation of carbon dioxide loss upon collision activation dissociation. Profile algorithm mass spectrometry data were acquired with mass resolving power (MRP) of 60,000. Quantitation was based on the extracted ion chromatography (EIC) peak area signal, which was extracted at m/z 188.9515 with a mass extraction window (MEW) of 5ppm. The UHPLC/HRQMS method was validated based on International Conference on Harmonization (ICH) guidelines, which included selectivity, limit of detection (LOD), limit of quantitation (LOQ), repeatability, linearity, accuracy, and stability.

[1]  A. Queen.  Kinetics of the hydrolysis of acyl chlorides in pure water , 1967 .

[2]  James C. Reynolds,et al.  Direct Detection of a Sulfonate Ester Genotoxic Impurity by Atmospheric-Pressure Thermal Desorption–Extractive Electrospray–Mass Spectrometry , 2013, Analytical chemistry.

[3]  P. Richardson,et al.  In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 Against Multiple Myeloma Cells , 2011 .

[4]  P. Richardson,et al.  In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells , 2011, Clinical Cancer Research.

[5]  T. Olah,et al.  Targeted quantitative bioanalysis in plasma using liquid chromatography/high-resolution accurate mass spectrometry: an evaluation of global selectivity as a function of mass resolving power and extraction window, with comparison of centroid and profile modes. , 2011, Rapid communications in mass spectrometry : RCM.

[6]  F. Bouder.  Regulating impurities in pharmaceutical products: a tolerability of risk approach? , 2008, Expert review of clinical pharmacology.

[7]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[8]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[9]  T. McGovern,et al.  Regulation of genotoxic and carcinogenic impurities in drug substances and products , 2006 .

[10]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[11]  D. Norwood,et al.  Genotoxic Impurities: A Quantitative Approach , 2008 .

[12]  P R Kakadiya,et al.  Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir Active pharmaceutical ingredients by LC/MS/MS using electrospray ionization. , 2011, Journal of pharmaceutical and biomedical analysis.

[13]  Jian-jun Zhao,et al.  Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. , 2012, Blood.

[14]  Jan G Hengstler,et al.  Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. , 2004, Toxicology letters.

[15]  P. Shah,et al.  The practical application of implementing the equimolar response principle of chemiluminescent nitrogen detection in pharmaceutical analysis. , 2008, Journal of pharmaceutical and biomedical analysis.

[16]  R. A. Scott,et al.  Use of 2-mercaptopyridine for the determination of alkylating agents in complex matrices: application to dimethyl sulfate. , 2005, Talanta.

[17]  R. Ogilvie,et al.  Acceptability of Low Levels of Genotoxic Impurities in New Drug Substances , 2012, International Journal of Pharmaceutical Medicine.

[18]  D. Elder,et al.  Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs). , 2008, Journal of pharmaceutical and biomedical analysis.

[19]  J. Miller,et al.  Mycotoxins in grain: compounds other than aflatoxin. , 1994 .

[20]  J. Donato,et al.  Analysis of nitrofuran metabolic residues in salt by liquid chromatography–tandem mass spectrometry , 2004 .

[21]  T. Olah,et al.  Full-scan high resolution accurate mass spectrometry (HRMS) in regulated bioanalysis: LC-HRMS for the quantitation of prednisone and prednisolone in human plasma. , 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[22]  Lutz Müller,et al.  A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. , 2006, Regulatory toxicology and pharmacology : RTP.